Apokyn Approval History
- FDA approved: Yes (First approved April 20th, 2004)
- Brand name: Apokyn
- Generic name: apomorphine
- Company: Bertek Pharmaceuticals
- Treatment for: Parkinson's Disease
Apokyn (apomorphine) is a non-ergoline dopamine agonist indicated for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) associated with advanced Parkinson’s disease.
Development History and FDA Approval Process for Apokyn
|Apr 20, 2004||Apokyn Bertek Pharmaceuticals - Treatment for Parkinson’s Disease|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.